Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other financing activities (2016 - 2025)

Historic Other financing activities for Coherus Oncology (CHRS) over the last 11 years, with Q3 2025 value amounting to $3000.0.

  • Coherus Oncology's Other financing activities fell 7000.0% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 6022.26%. This contributed to the annual value of $2.5 million for FY2024, which is 2979.87% down from last year.
  • Latest data reveals that Coherus Oncology reported Other financing activities of $3000.0 as of Q3 2025, which was down 7000.0% from $16000.0 recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Other financing activities registered a high of $4.6 million during Q4 2022, and its lowest value of -$2.0 million during Q2 2021.
  • For the 5-year period, Coherus Oncology's Other financing activities averaged around $1.2 million, with its median value being $642000.0 (2022).
  • Per our database at Business Quant, Coherus Oncology's Other financing activities tumbled by 10910.95% in 2021 and then skyrocketed by 46098.36% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Other financing activities stood at $2.2 million in 2021, then soared by 105.12% to $4.6 million in 2022, then decreased by 5.28% to $4.4 million in 2023, then plummeted by 44.22% to $2.4 million in 2024, then tumbled by 99.88% to $3000.0 in 2025.
  • Its Other financing activities was $3000.0 in Q3 2025, compared to $16000.0 in Q2 2025 and $264000.0 in Q1 2025.